Royalty Pharma plc RPRX
No target with a reported result yet
Releases of the last 3 yearsThe numbers RPRX said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Operating cash flow Fiscal 2026 |
Given $3.33B to $3.45B release May 6, 2026
Raised $3.40B to $3.50B release Aug 5, 2026
Raised $3.50B to $3.55B release Nov 4, 2026
|
– | Not reported yet | |
The company's wordsRoyaltyReceipts growth of 13% Net cash provided by operating activities of $718 million Raisedfull year 2026 guidance: Portfolio Receipts expected to be$3,325 million to $3,450 million release May 6, 2026 RoyaltyReceipts growth of 14% Net cash provided by operating activities of $728 million Raised full year 2026 guidance: Portfolio Receipts expected to be$3,400 million to $3,500 million release Aug 5, 2026 RoyaltyReceipts growth of 9% Net cash provided by operating activities of $686 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million release Nov 4, 2026 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (14 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RPRX/export.csv") into a cell.